Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis™, its innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
Company profile
Ticker
WGS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
CM Life Sciences, Inc., Sema4 Holdings Corp.
SEC CIK
Corporate docs
Subsidiaries
Sema4 OpCo, Inc. • GeneDx, LLC ...
IRS number
851966622
WGS stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
23 Feb 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
20 Feb 24
8-K
GeneDx Announces Preliminary 2023 Financial Results
8 Jan 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
30 Oct 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
S-8
Registration of securities for employees
8 Aug 23
8-K
GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights
8 Aug 23
8-K
Departure of Directors or Certain Officers
24 Jul 23
Transcripts
WGS
Earnings call transcript
2023 Q4
20 Feb 24
WGS
Earnings call transcript
2023 Q3
30 Oct 23
WGS
Earnings call transcript
2023 Q2
8 Aug 23
WGS
Earnings call transcript
2023 Q1
9 May 23
WGS
Earnings call transcript
2022 Q4
14 Mar 23
WGS
Earnings call transcript
2022 Q3
14 Nov 22
WGS
Earnings call transcript
2022 Q2
16 Aug 22
WGS
Earnings call transcript
2022 Q2
15 Aug 22
WGS
Earnings call transcript
2022 Q1
13 May 22
WGS
Earnings call transcript
2022 Q1
12 May 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 88.29 mm | 88.29 mm | 88.29 mm | 88.29 mm | 88.29 mm | 88.29 mm |
Cash burn (monthly) | 23.09 mm | 9.79 mm | 14.32 mm | 40.05 mm | 13.74 mm | 17.91 mm |
Cash used (since last report) | 138.16 mm | 58.56 mm | 85.70 mm | 239.64 mm | 82.23 mm | 107.18 mm |
Cash remaining | -49.87 mm | 29.73 mm | 2.59 mm | -151.36 mm | 6.06 mm | -18.89 mm |
Runway (months of cash) | -2.2 | 3.0 | 0.2 | -3.8 | 0.4 | -1.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 61 |
Opened positions | 48 |
Closed positions | 15 |
Increased positions | 2 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 51.21 bn |
Total shares | 1.50 bn |
Total puts | 27.30 k |
Total calls | 256.79 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
School Of Medicine At Mount Sinai Icahn | 1.23 bn | $523.26 mm |
OPK Opko Health | 117.43 mm | $34.15 mm |
CMLS | 109.15 mm | $31.54 mm |
Blackstone Holdings III | 27.80 mm | $11.81 mm |
Corvex Management | 3.31 mm | $12.04 bn |
Casdin Capital | 3.10 mm | $11.27 bn |
Integrated Core Strategies | 1.28 mm | $5.71 mm |
Deerfield Management | 1.25 mm | $4.56 bn |
Flynn James E | 1.25 mm | $0.00 |
Oracle Investment Management | 994.58 k | $3.62 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Katherine Stueland | Class A Common Stock | Sell | Dispose S | No | No | 10.5925 | 8,559 | 90.66 k | 66,698 |
18 Mar 24 | Kareem Saad | Class A Common Stock | Sell | Dispose S | No | No | 10.5923 | 2,008 | 21.27 k | 29,517 |
18 Mar 24 | Kevin Feeley | Class A Common Stock | Sell | Dispose S | No | No | 10.5917 | 3,253 | 34.45 k | 28,927 |
16 Mar 24 | Katherine Stueland | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 18,750 | 0.00 | 75,257 |
16 Mar 24 | Katherine Stueland | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 18,750 | 0.00 | 225,000 |
16 Mar 24 | Kareem Saad | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 5,114 | 0.00 | 31,525 |
16 Mar 24 | Kareem Saad | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 5,114 | 0.00 | 61,362 |
16 Mar 24 | Kevin Feeley | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 7,197 | 0.00 | 32,180 |
16 Mar 24 | Kevin Feeley | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 7,197 | 0.00 | 86,363 |
12 Mar 24 | Kevin Feeley | Class A Common Stock | Sell | Dispose S | No | No | 9.2097 | 931 | 8.57 k | 24,983 |
News
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
18 Mar 24
GeneDx To Present Data At The 2024 American College Of Medical Genetics Annual Meeting Demonstrating Clinical Superiority Of Its Exome
14 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
8 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
22 Feb 24
GeneDx Hldgs Q4 Adj EPS $(0.69) Beats $(0.75) Estimate, Sales $57.42M Beat $55.43M Estimate
20 Feb 24
Press releases
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
20 Feb 24
GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
1 Feb 24
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 Jan 24
GeneDx Announces Preliminary 2023 Financial Results
8 Jan 24